1.98
price down icon1.00%   -0.02
 
loading
Schlusskurs vom Vortag:
$2.00
Offen:
$2.01
24-Stunden-Volumen:
515.96K
Relative Volume:
0.43
Marktkapitalisierung:
$280.26M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-35.47M
KGV:
-3.4737
EPS:
-0.57
Netto-Cashflow:
$-124.27M
1W Leistung:
+14.45%
1M Leistung:
-15.02%
6M Leistung:
-11.61%
1J Leistung:
+28.57%
1-Tages-Spanne:
Value
$1.91
$2.02
1-Wochen-Bereich:
Value
$1.74
$2.12
52-Wochen-Spanne:
Value
$0.4603
$7.13

Prokidney Corp Stock (PROK) Company Profile

Name
Firmenname
Prokidney Corp
Name
Telefon
336-999-7028
Name
Adresse
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM
Name
Mitarbeiter
204
Name
Twitter
Name
Nächster Verdiensttermin
2024-12-09
Name
Neueste SEC-Einreichungen
Name
PROK's Discussions on Twitter

Compare PROK vs VRTX, REGN, ARGX, ALNY, ONC

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
PROK
Prokidney Corp
1.98 283.09M 0 -35.47M -124.27M -0.57
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
465.02 117.03B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
783.65 82.35B 14.34B 4.50B 3.77B 41.56
Biotechnology icon
ARGX
Argen X Se Adr
833.54 51.64B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
308.48 42.58B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ONC
Beone Medicines Ltd Adr
346.42 38.87B 4.98B 69.60M 525.67M 0.5198

Prokidney Corp Stock (PROK) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-12-16 Eingeleitet H.C. Wainwright Buy
2025-06-30 Herabstufung BofA Securities Neutral → Underperform
2024-09-30 Eingeleitet JP Morgan Neutral
2024-09-10 Eingeleitet Guggenheim Buy
2024-03-07 Fortgesetzt Morgan Stanley Equal-Weight
2024-01-02 Herabstufung BofA Securities Buy → Neutral
2023-07-25 Eingeleitet BTIG Research Buy
2022-12-21 Eingeleitet Jefferies Buy
2022-11-10 Eingeleitet Morgan Stanley Equal-Weight
2022-10-18 Eingeleitet UBS Buy
2022-10-14 Eingeleitet Citigroup Buy
2022-09-23 Eingeleitet BofA Securities Buy
2022-09-02 Eingeleitet Evercore ISI Outperform
Alle ansehen

Prokidney Corp Aktie (PROK) Neueste Nachrichten

pulisher
Feb 09, 2026

Is ProKidney Corp. stock a top performer YTDInflation Watch & Free Reliable Trade Execution Plans - mfd.ru

Feb 09, 2026
pulisher
Feb 06, 2026

Here's Why We're Watching ProKidney's (NASDAQ:PROK) Cash Burn Situation - 富途牛牛

Feb 06, 2026
pulisher
Feb 05, 2026

Revenue Check: Will ProKidney Corp benefit from geopolitical trendsBreakout Watch & Weekly High Return Forecasts - baoquankhu1.vn

Feb 05, 2026
pulisher
Feb 05, 2026

Will ProKidney Corp. stock keep outperforming rivalsJuly 2025 Price Swings & Fast Moving Market Watchlists - mfd.ru

Feb 05, 2026
pulisher
Feb 05, 2026

Layoff Watch: Does ProKidney Corp offer margin of safety2025 Buyback Activity & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn

Feb 05, 2026
pulisher
Feb 04, 2026

ProKidney Corp Explodes Into the Spotlight: Breakthrough Stock or Overhyped Trap? - AD HOC NEWS

Feb 04, 2026
pulisher
Feb 04, 2026

HC Wainwright Forecasts ProKidney FY2030 Earnings - MarketBeat

Feb 04, 2026
pulisher
Feb 03, 2026

Growth Value: Will CVCO benefit from sector rotationJuly 2025 WrapUp & Risk Controlled Swing Trade Alerts - baoquankhu1.vn

Feb 03, 2026
pulisher
Feb 03, 2026

Is ProKidney Corp stock undervalued right nowMarket Growth Review & Low Risk High Win Rate Stock Picks - baoquankhu1.vn

Feb 03, 2026
pulisher
Feb 03, 2026

ProKidney Shares Soar After Citi Lifts Price Target to $9 - MSN

Feb 03, 2026
pulisher
Feb 02, 2026

ProKidney: Preserved Long-Term Opportunity but Heightened Timeline Risk Supports Continued Hold Rating - TipRanks

Feb 02, 2026
pulisher
Feb 02, 2026

ProKidney Expands Phase 3 REGEN-006 Trial Enrollment Plans - TipRanks

Feb 02, 2026
pulisher
Feb 02, 2026

ProKidney CorpTopline data readout of surrogate endpoint expected Q2 2027 - marketscreener.com

Feb 02, 2026
pulisher
Feb 02, 2026

Prokidney CorpTopline Data Readout Of Surrogate Endpoint Expected Q2 2027 - TradingView

Feb 02, 2026
pulisher
Jan 31, 2026

ProKidney Stock: Differentiated CKD Approach Positions Rilparencel Favorably (NASDAQ:PROK) - Seeking Alpha

Jan 31, 2026
pulisher
Jan 31, 2026

ProKidney Corp. (NASDAQ:PROK) Receives Average Rating of "Hold" from Analysts - MarketBeat

Jan 31, 2026
pulisher
Jan 29, 2026

Can ProKidney Corp. continue delivering strong returns2025 Biggest Moves & Daily Profit Maximizing Tips - mfd.ru

Jan 29, 2026
pulisher
Jan 29, 2026

Macro Review: Can CBTJ expand its profit margins2025 Volatility Report & Consistent Growth Equity Picks - baoquankhu1.vn

Jan 29, 2026
pulisher
Jan 27, 2026

Aug Action: Can ProKidney Corp be the next market leaderTreasury Yields & Stock Portfolio Risk Management - baoquankhu1.vn

Jan 27, 2026
pulisher
Jan 27, 2026

Why is ProKidney Corp. stock going downWeekly Trade Report & Fast Gain Stock Tips - mfd.ru

Jan 27, 2026
pulisher
Jan 26, 2026

Ideas Watch: Should I buy ProKidney Corp stock nowTrade Performance Summary & Fast Entry High Yield Stock Tips - baoquankhu1.vn

Jan 26, 2026
pulisher
Jan 21, 2026

Profit Review: Does ProKidney Corp outperform in volatile marketsTrade Entry Report & Technical Entry and Exit Alerts - baoquankhu1.vn

Jan 21, 2026
pulisher
Jan 19, 2026

Investment Review: Does ProKidney Corp offer margin of safety2025 Support & Resistance & Risk Controlled Daily Trade Plans - baoquankhu1.vn

Jan 19, 2026
pulisher
Jan 15, 2026

PROKProKidney Latest Stock News & Market Updates - Stock Titan

Jan 15, 2026
pulisher
Jan 15, 2026

ProKidney (NASDAQ:PROK) Stock Price Down 5.5%What's Next? - MarketBeat

Jan 15, 2026
pulisher
Jan 15, 2026

Risk Recap: Why is ProKidney Corp stock going downPortfolio Update Report & Free Growth Oriented Trading Recommendations - baoquankhu1.vn

Jan 15, 2026
pulisher
Jan 15, 2026

Bear Alert: Why is ProKidney Corp stock going downCPI Data & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn

Jan 15, 2026
pulisher
Jan 14, 2026

H.C. Wainwright Maintains ProKidney(PROK.US) With Buy Rating, Maintains Target Price $12 - 富途牛牛

Jan 14, 2026
pulisher
Jan 14, 2026

PROK: Pivotal phase III trial of rilparencel for advanced CKD targets Q2 2027 readout, with strong phase II results - TradingView

Jan 14, 2026
pulisher
Jan 12, 2026

Recap Report: What is the cash position of ProKidney CorpBuy Signal & Free High Return Stock Watch Alerts - baoquankhu1.vn

Jan 12, 2026
pulisher
Jan 12, 2026

ProKidney Advances Rilparencel Program and Manufacturing Expansion - TipRanks

Jan 12, 2026
pulisher
Jan 12, 2026

ProKidney Corp Updates on Rilparencel and Phase 3 Trials - TradingView

Jan 12, 2026
pulisher
Jan 10, 2026

Will ProKidney Corp. stock maintain momentum in 2025Bull Run & Consistent Return Investment Signals - ulpravda.ru

Jan 10, 2026
pulisher
Jan 08, 2026

Why ProKidney Corp. stock could benefit from AI revolutionJuly 2025 Outlook & Risk Managed Investment Strategies - Улправда

Jan 08, 2026
pulisher
Jan 08, 2026

Earnings Update: How interest rate cuts could boost ProKidney Corp. stockJuly 2025 Levels & Community Driven Trade Alerts - Улправда

Jan 08, 2026
pulisher
Jan 08, 2026

Is ProKidney Corp. stock attractive for passive investorsMarket Movement Recap & Reliable Intraday Trade Alerts - Улправда

Jan 08, 2026
pulisher
Jan 08, 2026

Retail Trends: Why ProKidney Corp. stock could benefit from AI revolutionPortfolio Gains Summary & Fast Gain Stock Tips - Улправда

Jan 08, 2026
pulisher
Jan 08, 2026

Is ProKidney Corp. stock supported by strong fundamentalsEarnings Growth Summary & Weekly Market Pulse Alerts - Улправда

Jan 08, 2026
pulisher
Jan 08, 2026

3 Penny Stocks With Market Caps Under $700M - simplywall.st

Jan 08, 2026
pulisher
Jan 07, 2026

Is ProKidney Corp. stock a buy on dipsDouble Top/Bottom Patterns & Rapid Profit Growth - ulpravda.ru

Jan 07, 2026
pulisher
Jan 07, 2026

ProKidney (NASDAQ:PROK) Trading 6.9% HigherTime to Buy? - MarketBeat

Jan 07, 2026
pulisher
Jan 06, 2026

ProKidney Corp. CEO Bruce Culleton to Present at 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative

Jan 06, 2026
pulisher
Jan 06, 2026

ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times

Jan 06, 2026
pulisher
Jan 06, 2026

ProKidney Corp. (NASDAQ:PROK) Given Consensus Rating of "Hold" by Analysts - MarketBeat

Jan 06, 2026
pulisher
Jan 04, 2026

ProKidney Shares Dip Following FDA Agreement on Rilparencel Approval Strategy - MSN

Jan 04, 2026
pulisher
Jan 02, 2026

PROKIDNEY CP (PROK) Upgraded to Strong Buy: What Does It Mean for the Stock? - MSN

Jan 02, 2026
pulisher
Dec 29, 2025

ProKidney (NASDAQ:PROK) Shares Down 7.3%Should You Sell? - MarketBeat

Dec 29, 2025
pulisher
Dec 28, 2025

B of A Securities Downgrades ProKidney (PROK) - MSN

Dec 28, 2025
pulisher
Dec 28, 2025

PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study - MSN

Dec 28, 2025
pulisher
Dec 27, 2025

ProKidney Corp. (PROK) positioned to redefine chronic kidney disease treatment, believes HC Wainwright - MSN

Dec 27, 2025
pulisher
Dec 27, 2025

ProKidney Corp. (PROK) Positioned to Redefine Chronic Kidney Disease Treatment, Believes H.C. Wainwright - Yahoo Finance

Dec 27, 2025

Finanzdaten der Prokidney Corp-Aktie (PROK)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$44.80
price up icon 1.24%
$26.75
price down icon 0.19%
$100.75
price up icon 1.93%
$105.76
price down icon 3.31%
$146.17
price down icon 1.52%
biotechnology ONC
$346.42
price down icon 1.38%
Kapitalisierung:     |  Volumen (24h):